The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
The Community Focus Channel is supported with funding from Johnson & Johnson (Gold).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2024 | Menin inhibitors in AML: efficacy, safety, and future considerations with these agents
In this video, Chong Chyn Chua, MBBS, FRACP, FRCPA, The Alfred Hospital and Monash University, Melbourne, Australia, comments on the emergence of menin inhibitors in the treatment of acute myeloid leukemia (AML), emphasizing the excitement around these agents. Dr Chua highlights the promising single-agent response rates that have been observed in relapsed/refractory (R/R) disease and further shares her thoughts on the future of these agents in various settings. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
